Momenta Pharmaceuticals to Webcast Presentation at Cowen and Company's 35th Annual Health Care Conference
18 févr. 2015 08h30 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results
17 févr. 2015 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2014.
For the...
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2014 Financial Results Conference Call and Webcast
03 févr. 2015 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
29 janv. 2015 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Supreme Court Decision to Remand Generic Copaxone(R) Case Back to CAFC
21 janv. 2015 08h30 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Jan. 21, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the United States Supreme Court has vacated the 2013 decision of the Court of...
Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer
01 déc. 2014 08h15 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Acceptance of a Clinical Trial Application in Europe for M923, a Biosimilar Version of Humira(R)
01 déc. 2014 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals to Webcast Presentation at 2014 Deutsche Bank BioFEST
24 nov. 2014 16h30 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals to Webcast Presentation at Three Upcoming Investor Conferences
06 nov. 2014 08h30 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Reports Third Quarter 2014 Financial Results
05 nov. 2014 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...